<DOC>
	<DOCNO>NCT02505048</DOCNO>
	<brief_summary>The purpose study assess efficacy PARP inhibitor , rucaparib , progress breast cancer patient carry BCRAness profile define genomic signature BRCA 1 2 somatic mutation , without know BRCA 1 2 germline mutation .</brief_summary>
	<brief_title>A Study Assess Efficacy Rucaparib Metastatic Breast Cancer Patients With BRCAness Genomic Signature</brief_title>
	<detailed_description>This single arm , open-label , multicentric , phase II trial , Simon two-stage design , assess efficacy PARP inhibitor , rucaparib , 41 progress breast cancer patient least one line chemotherapy metastatic setting. , carry BRCAness profile define Clovis genomic signature BRCA1 2 somatic mutation , without know BRCA1 2 germline mutation .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Rucaparib</mesh_term>
	<criteria>1 . Women histologically proven breast cancer . 2 . No Her2 overexpression . 3 . Progressive metastatic disease previously treat least one line chemotherapy metastatic setting . 4 . Molecular analysis use Affymetrix ( CytoScan HD , SNP 6.0 , OncoScan ) array available SAFIR02 protocol , program . 5 . BRCAness profile define Clovis genomic signature BRCA1/2 somatic mutation ( without know germline BRCA ) . 6 . Age ≥ 18 year 7. WHO Performance Status 0/1 8 . Presence measurable target lesion accord RECIST criterion v1.1 9 . Patients least 21day washout period last chemotherapy target therapy administration prior inclusion recover ( grade ≤1 ) residual toxicity , exclude alopecia . 10 . Potentially reproductive patient must agree use effective contraceptive nonhormonal method practice adequate method birth control practice complete abstinence treatment , least 6 month last dose study drug . 11 . Women childbearing potential must negative serum pregnancy test do within 14 day enrollment and/or urine pregnancy test 72 hour prior administration study drug . 12 . Women breastfeed discontinue nursing prior first dose study drug 6 month last dose . 13 . Provision sign date , write informed consent prior study specific procedure , sample analysis 14 . Patient social insurance coverage . 1 . BRCA1 2 germline know mutation . 2 . Life expectancy &lt; 3 month . 3 . Less 14 day radiotherapy ( whatever indication ) . Fields involve target lesion . 4 . Patients previously treat PARP inhibitor . 5 . Spinal cord compression and/or symptomatic progressive brain metastasis ( unless asymptomatic treat stable steroid least 30 day prior start study drug ) . 6 . Patients target lesion previously irradiate region , except clear progression observe prior study least one 7 . Inability swallow 8 . Major problem intestinal absorption 9 . Previous current malignancy histology within last 5 year , exception situ carcinoma cervix , adequately treat basal cell squamous cell carcinoma skin . 10 . Evidence severe uncontrolled systemic disease ( active bleeding diatheses , active Hepatitis B , C HIV ) 11 . Previous history myelodysplastic syndrome 12 . History hypersensitivity active inactive excipients rucaparib . 13 . Toxicities grade ≥2 previous anticancer therapy , exception alopecia . 14 . Altered haematopoietic organ function , indicate follow criterion : Polynuclear neutrophils &lt; 1.5 x 109/L Platelets &lt; 100 x 109/L Haemoglobin &lt; 90 g/L ALAT/ASAT &gt; 2.5x ULN absence &gt; 5x ULN presence liver metastases Bilirubin &gt; 1.5xULN Creatinine clearance ≤30 mL/min ( measure calculate Cockroft Gault formula 15 . Women pregnant . 16 . Patients use drug know potent inhibitor potent inducer CYP1A2 CYP3A4 eligible treatment substitute inclusion 17 . Any condition Investigator 's opinion make undesirable subject participate trial would jeopardize compliance protocol . 18 . Individuals deprive liberty place authority tutor .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>